Hayoung Choi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hayoung Choi has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Myungshin Kim
Department of Laboratory Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
4 shared publications - Yonggoo Kim
Department of Laboratory Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
4 shared publications Gun Dong Lee
Catholic Genetic Laboratory Center, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
3 shared publications- Dain Kang
Catholic Genetic Laboratory Center, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
2 shared publications - Dong-Gun Lee
Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
2 shared publications - Jaewoong Lee
Department of Laboratory Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea
2 shared publications
Latest Publications
- Open Access
- 18 September 2021
- Published by Springer Nature in Molecular Diagnosis & Therapy
- Vol. 25 (6) , 811
Correction to: Analytical and Clinical Performance of Droplet Digital PCR in the Detection and Quantification of SARS-CoV-2
- 18 September 2021
- Published by Springer Nature in Molecular Diagnosis & Therapy
- Vol. 25 (6) , 811
Open AccessCorrection to: Analytical and Clinical Performance of Droplet Digital PCR in the Detection and Quantification of SARS-CoV-2
- Open Access
- 28 July 2021
- Published by Springer Nature in Molecular Diagnosis & Therapy
- Vol. 25 (5) , 617-628
Analytical and Clinical Performance of Droplet Digital PCR in the Detection and Quantification of SARS-CoV-2
Background and Objective Since the initial coronavirus disease outbreak in late 2019 (COVID-19), reverse-transcription real-time polymerase chain reaction (RT-qPCR) has become the gold standard test to detect severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2). However, a more sensitive and accurate diagnostic tool was required. Therefore, droplet digital polymerase chain reaction (ddPCR) was suggested as an alternative method. Here, we evaluated the performance of ddPCR to detect SARS-CoV-2 and compared it to the performance of RT-qPCR. Methods The analytical performances, including limit of blank and limit of detection, were established using positive and negative SARS-CoV-2 reference materials. A total of 366 RNA extracts (173 positive and 193 negative by RT-qPCR) were collected from four institutions and tested with a Bio-Rad SARS-CoV-2 ddPCR kit that detects the SARS-CoV-2 genome using primers for N1 and N2. Results Limit of blank was set at 0, and the limits of detection of N1 and N2 were 1.99 copies/μL and 5.18 copies/μL, respectively. Linearity was evaluated using serial dilution samples, which demonstrated good results (R2: 0.999, linear range: 5.88–6825.25 copies/μL for N1 and R2: 0.999, 5.53–5855.47 copies/μL for N2). The results of ddPCR and RT-qPCR revealed substantial agreement (Cohen’s kappa: 0.639, p < 0.01). The 63 samples with positive ddPCR but negative RT-qPCR showed low copy numbers, and 55% of them had COVID-19-related symptoms. Conclusions Droplet digital polymerase chain reaction demonstrated excellent sensitivity for SARS-Cov-2 detection and consistently agreed with the results from conventional RT-qPCR. Furthermore, ddPCR provided quantitative data that can be used to monitor changes in the viral load of patients with COVID-19.
- 28 July 2021
- Published by Springer Nature in Molecular Diagnosis & Therapy
- Vol. 25 (5) , 617-628
Open AccessAnalytical and Clinical Performance of Droplet Digital PCR in the Detection and Quantification of SARS-CoV-2
Background and Objective Since the initial coronavirus disease outbreak in late 2019 (COVID-19), reverse-transcription real-time polymerase chain reaction (RT-qPCR) has become the gold standard test to detect severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2). However, a more sensitive and accurate diagnostic tool was required. Therefore, droplet digital polymerase chain reaction (ddPCR) was suggested as an alternative method. Here, we evaluated the performance of ddPCR to detect SARS-CoV-2 and compared it to the performance of RT-qPCR. Methods The analytical performances, including limit of blank and limit of detection, were established using positive and negative SARS-CoV-2 reference materials. A total of 366 RNA extracts (173 positive and 193 negative by RT-qPCR) were collected from four institutions and tested with a Bio-Rad SARS-CoV-2 ddPCR kit that detects the SARS-CoV-2 genome using primers for N1 and N2. Results Limit of blank was set at 0, and the limits of detection of N1 and N2 were 1.99 copies/μL and 5.18 copies/μL, respectively. Linearity was evaluated using serial dilution samples, which demonstrated good results (R2: 0.999, linear range: 5.88–6825.25 copies/μL for N1 and R2: 0.999, 5.53–5855.47 copies/μL for N2). The results of ddPCR and RT-qPCR revealed substantial agreement (Cohen’s kappa: 0.639, p < 0.01). The 63 samples with positive ddPCR but negative RT-qPCR showed low copy numbers, and 55% of them had COVID-19-related symptoms. Conclusions Droplet digital polymerase chain reaction demonstrated excellent sensitivity for SARS-Cov-2 detection and consistently agreed with the results from conventional RT-qPCR. Furthermore, ddPCR provided quantitative data that can be used to monitor changes in the viral load of patients with COVID-19.
- Open Access
- 1 March 2021
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 41 (2) , 198-206
Targeted Next-Generation Sequencing of Plasma Cell-Free DNA in Korean Patients with Hepatocellular Carcinoma
Hyojin Chae, M.D., Ph.D., Pil Soo Sung, M.D., Ph.D., Hayoung Choi, M.S., Ahlm Kwon, M.S., Dain Kang, B.S.E., Yonggoo Kim, M.D., Ph.D., Myungshin Kim, M.D., Ph.D., and Seung Kew Yoon, M.D., Ph.D.. Ann Lab Med 2021;41:198-206. https://doi.org/10.3343/alm.2021.41.2.198
- 1 March 2021
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 41 (2) , 198-206
Open AccessTargeted Next-Generation Sequencing of Plasma Cell-Free DNA in Korean Patients with Hepatocellular Carcinoma
Hyojin Chae, M.D., Ph.D., Pil Soo Sung, M.D., Ph.D., Hayoung Choi, M.S., Ahlm Kwon, M.S., Dain Kang, B.S.E., Yonggoo Kim, M.D., Ph.D., Myungshin Kim, M.D., Ph.D., and Seung Kew Yoon, M.D., Ph.D.. Ann Lab Med 2021;41:198-206. https://doi.org/10.3343/alm.2021.41.2.198
- 16 July 2020
- Published by Springer Nature in Molecular Diagnosis & Therapy
- Vol. 24 (5) , 579-592
Analytical and Potential Clinical Performance of Oncomine Myeloid Research Assay for Myeloid Neoplasms
Introduction Next-generation sequencing (NGS) panels have recently been introduced to efficiently detect genetic variations in hematologic malignancies. Objectives Our aim was to evaluate the performance of the commercialized Oncomine™ myeloid research assay (OMA) for myeloid neoplasms. Methods Certified reference materials and clinical research samples were used, including 60 genomic DNA and 56 RNA samples. NGS was performed using OMA, which enables the interrogation of 40 target genes, 29 gene fusions, and five expression target genes with five expression control genes by the Ion S5 XL Sequencer. The analyzed data were compared with clinical data using karyotyping, reverse transcription polymerase chain reaction (PCR), fluorescence in situ hybridization, Sanger sequencing, customized NGS panel, and fragment analysis. Results All targets of reference materials were detected except three (two ASXL1 and one CEBPA) mutations, which we had not expected OMA to detect. In clinical search samples, OMA satisfactorily identified DNA variants, including 90 single nucleotide variants (SNVs), 48 small insertions and deletions (indels), and eight FLT3 internal tandem duplications (ITDs) (Kappa agreement 0.938). The variant allele frequencies of SNVs and indels measured by OMA correlated well with clinical data, whereas those of FLT3-ITDs were significantly lower than with fragment analysis (P = 0.008). Together, OMA showed strong ability to identify RNA gene fusions (Kappa agreement 0.961), except one RUNX1-MECOM. The MECOM gene was highly expressed in all five samples with MECOM-associated rearrangements, including inv(3), t(3;3), and t(3;21). Conclusion OMA revealed excellent analytical and potential clinical performance and could be a good replacement for conventional molecular tests.
- 16 July 2020
- Published by Springer Nature in Molecular Diagnosis & Therapy
- Vol. 24 (5) , 579-592
Analytical and Potential Clinical Performance of Oncomine Myeloid Research Assay for Myeloid Neoplasms
Introduction Next-generation sequencing (NGS) panels have recently been introduced to efficiently detect genetic variations in hematologic malignancies. Objectives Our aim was to evaluate the performance of the commercialized Oncomine™ myeloid research assay (OMA) for myeloid neoplasms. Methods Certified reference materials and clinical research samples were used, including 60 genomic DNA and 56 RNA samples. NGS was performed using OMA, which enables the interrogation of 40 target genes, 29 gene fusions, and five expression target genes with five expression control genes by the Ion S5 XL Sequencer. The analyzed data were compared with clinical data using karyotyping, reverse transcription polymerase chain reaction (PCR), fluorescence in situ hybridization, Sanger sequencing, customized NGS panel, and fragment analysis. Results All targets of reference materials were detected except three (two ASXL1 and one CEBPA) mutations, which we had not expected OMA to detect. In clinical search samples, OMA satisfactorily identified DNA variants, including 90 single nucleotide variants (SNVs), 48 small insertions and deletions (indels), and eight FLT3 internal tandem duplications (ITDs) (Kappa agreement 0.938). The variant allele frequencies of SNVs and indels measured by OMA correlated well with clinical data, whereas those of FLT3-ITDs were significantly lower than with fragment analysis (P = 0.008). Together, OMA showed strong ability to identify RNA gene fusions (Kappa agreement 0.961), except one RUNX1-MECOM. The MECOM gene was highly expressed in all five samples with MECOM-associated rearrangements, including inv(3), t(3;3), and t(3;21). Conclusion OMA revealed excellent analytical and potential clinical performance and could be a good replacement for conventional molecular tests.